http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-4950523-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6464 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21069 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 |
| filingDate | 1998-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9e237241204f9109874f6ce80df5510 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_504cb0600ea65f4e913b5fe624136f0f |
| publicationDate | 2000-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CO-4950523-A1 |
| titleOfInvention | ACTIVATED PROTEIN C FORMULATIONS |
| abstract | A stable lyophilized formulation comprising Cactivated protein and a bulking agent selected from the group consisting of mannite, trehalose, mellose and sucrose, and mixtures thereof. The formulation according to Claim 1, in which the bulking agent is sucrose , trehalose or mellose. The formulation according to Claim 2, in which the bulking agent is sucrose. The formulation according to Claim 1, further comprising a pharmaceutically acceptable salt. The formulation according to Claim 4, in which the weight ratio is approximately one part of activated protein C, approximately between 7 to 8 parts of salt, and approximately between 5 to 7 parts of bulking agent. The formulation according to Claim 5, in which the weight ratio is approximately one part activated protein C, approximately 7.6 parts salt and approximately 6 parts bulking agent. The formulation according to Claim 6, wherein the salt is NaCl, and the bulking agent is sucrose. The formulation according to any one of Claims 1 to 7, which further comprises sodium citrate. A stable lyophilized formulation comprising approximately 2.5 mg / mL activated protein C, approximately 15 mg / mL sucrose, and approximately 20 mg / mL NaCl A stable lyophilized formulation comprising approximately 5 mg / mL activated protein C, approximately 30 mg / mL sucrose, and approximately 38 mg / mL NaCl.1 A process to prepare the formulation according to any one of Claims 1 to 10, which comprises lyophilizing a solution comprising activated protein C and a bulking agent selected from the group consisting of mannite, trehalose, mellose and sucrose, and mixtures thereof. |
| priorityDate | 1997-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 55.